Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
OMS-1029 by Omeros for Unspecified Immunological Disorders: Likelihood of Approval
OMS-1029 is under clinical development by Omeros and currently in Phase I for Unspecified Immunological Disorders. According to GlobalData, Phase...
Narsoplimab by Omeros for Coronavirus Disease 2019 (COVID-19): Likelihood of Approval
Narsoplimab is under clinical development by Omeros and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData,...
Zaltenibart by Omeros for Paroxysmal Nocturnal Hemoglobinuria: Likelihood of Approval
Zaltenibart is under clinical development by Omeros and currently in Phase II for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase...
Zaltenibart by Omeros for Kidney Disease (Nephropathy): Likelihood of Approval
Zaltenibart is under clinical development by Omeros and currently in Phase I for Kidney Disease (Nephropathy). According to GlobalData, Phase...
Zaltenibart by Omeros for Glomerulonephritis: Likelihood of Approval
Zaltenibart is under clinical development by Omeros and currently in Phase II for Glomerulonephritis. According to GlobalData, Phase II drugs...